InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...
H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...
InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...
InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...
INF-904 is under clinical development by InflaRx and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase ...
Overview: Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for viral infections, with a market ...
On Monday, H.C. Wainwright maintained its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), currently trading at $2.24, following the company's announcement on December 20 about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback